who hematolymphoid 5th edition pdf

Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EBVMCU: EBV-positive mucocutaneous ulcer. Revised 4th ed. Counting mitoses: SI(ze) matters! 2. and transmitted securely. Does anyone know when a 5th edition is going to be published? Figure 2. Lyon: IARC; 2017. The impact of these criteria on hematopathology practice is uncertain. Molecular genetic subtyping can further define the disease into a range of updated classifications (Figure 2). Following this, a multidisciplinary author team was formed including hematopathologists, hematologists, oncologists, geneticists, epidemiologist, molecular biologists, and other experts in the field. The classification in situ follicular neoplasia has been revised and is now termed in situ mantle cell neoplasm. 2021 May 1;145(5):607-626. doi: 10.5858/arpa.2020-0047-RA. Published: 21 March 2022. Show details Contents Table 4 Revised nomenclature and name changes of myeloid or mesenchymal neoplasms in the 5th edition compared with the revised 4th edition of WHO classification of hematolymphoid tumors AML, acute myeloid leukemia. The WHO Classification of Haematolymphoid Tumours. The classification of hematolymphoid neoplasms in the WHO Classification of Pediatric Tumors focuses on the landscape of these neoplasms in CAYA and is essentially an adaptation of the revised fourth edition of WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (Table 1; refs. For any comments or corrections, please email: WHO Blue Books Team 2022. 4. Mod Pathol. Besides listing the entities of the government site. Where the author is identified as personnel of the International Agency for Research on Cancer/World Health Organization, the author alone is responsible for the views expressed in this article, and does not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. 6. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. Histopathology. Most precursor B-cell neoplasms are classified based on ploidy changes, chromosomal rearrangements, or the presence of other genetic drivers. This has since been expanded to include genetics and radiology, reflecting the increasingly multidisciplinary nature of the entire classification [5, 6]. This rather dry phrasing led to the International Classification of Disease series of coding systems and the WHO Classification of Tumours. Bethesda, MD 20894, Web Policies Recently, the 5 th edition of the WHO classification of hematolymphoid tumors was released, with the online version available since August 2022, and the print version expected to be out at the end of 2022. 2023 Jan 3. doi: 10.5858/arpa.2022-0166-RA. There are several important changes in the WHO 5th edition hemato-lymphoid with a paradigm shift towards genetic diagnosis along with morphological aspects. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. Just got my book in the mail today! Int J Cancer. Leukemia. Summary of the relationship between, Fig. The . In addition, a dedicated meeting was organised to receive expert clinical haematology/oncology input on the clinical implications of some of the changes introduced in this edition. Unfortunately, the pace did not last: the 4th edition took from 2006 to 2018. Mod Pathol. Expert consensus, systematic reviews or both? Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hematolymphoid Proliferations and Neoplasia. Conflict of Interest: The author declares no potential conflicts of interest with respect to research, authorship and/or publication of this manuscript. ): World Health Organization classification of Tumours. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Gnudi F, Panzacchi S, Tibaldi E, Iuliani M, Sgargi D, Bua L, Mandrioli D. Ann Glob Health. We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Chapter 1. B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3); B-lymphoblastic leukaemia/lymphoma with other de, Pre-neoplastic and neoplastic small lymphocytic, Splenic B-cell lymphoma/leukaemia with prominent nucleoli, (encompassing hairy cell leukaemia variant and some, cases of B-cell prolymphocytic leukaemia), Extranodal marginal zone lymphoma of mucosa-associated, lymphoma of mucosa-associated lymphoid tissue, Do not sell or share my personal information. WHO hematolymphoid 2017.pdf - Free ebook download as PDF File (.pdf), Text File (.txt) or read book online for free. Careers. At the time of writing, the volume is now undergoing IARC editorial checking prior to technical editing. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Article 2021 May 1;145(5):607-626. doi: 10.5858/arpa.2020-0047-RA. New additions to B-cell lymphoid proliferations and lymphomas category*. The Blood papers said zero about the changes that the Myeloma Group recommended for plasma cell neoplasms. In line with the . Siebert R, Schuh A, Ott G, Cree IA, Du MQ, Ferry J, Hochhaus A, Naresh KN, Solary E, Khoury JD. In the 5th edition of the World Health Organization (WHO) Classification of Head and Neck Tumours, the discussion of hematolymphoid proliferations is substantially reorganized and expanded in comparison to the prior edition. Histopathology. This chapter provides a brief overview of the 5th edition of the WHO classification of hematolymphoid tumors with a focus on the changes and updates from a readers perspective. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study. Much more information on hematolymphoid proliferations that commonly . 2022;33:35. The outcome of this effort is another classification in the series that will help move the field forward by being based on a forward-looking multidisciplinary effort grounded in genetic advances, with an eye on worldwide applicability. Endocr Pathol. Please tick this box if you consent to receiving information from the pharmaceutical industry and other hub stakeholders. Epub 2022 Oct 14. Unable to load your collection due to an error, Unable to load your delegates due to an error. and transmitted securely. Following nomenclature updates to this family, the term splenic B-cell lymphoma/leukemia with prominent nucleoli now replaces both hairy cell leukemia variant and CD5-negative B-cell prolymphocytic leukemia. The WHO-HAEM5, like, all 5th Edition WHO tumour volumes, applies a hierarchical system, family/class (e.g., large B-cell lymphomas), entity/type (e.g., diffuse, large B-cell lymphoma, not otherwise speci, diffuse large B cell lymphoma, not otherwise speci, such that the implementation of the WHO-HAEM5 classi. Ferry JA. Bookshelf Please enable it to take advantage of the complete set of features! One such change is the reclassification of lymphoproliferative diseases associated with primary immune disorders to inborn error of immunity-associated lymphoid proliferations and lymphomas. Int J Cancer. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hematolymphoid Proliferations and Neoplasia. Lyon: IARC; 2008. This contrasts with the WHO Classification of Tumours editorial board. Google Scholar. Front Oncol. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. sharing sensitive information, make sure youre on a federal Prior to the 5th edition, we surveyed the readership and were told very clearly that the maximum tolerable update timing was 5 years: quite a challenge. 4th ed. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K. Ann Hematol. Haider Z, Wsterlid T, Spngberg LD, Rabbani L, Jylh C, Thorvaldsdottir B, Skaftason A, Awier HN, Krstic A, Gellerbring A, Lyander A, Hgglund M, Jeggari A, Rassidakis G, Sonnevi K, Sander B, Rosenquist R, Tham E, Smedby KE. Head Neck Pathol. government site. In addition, this family has seen the addition of three new entities: hyperplasias arising in immune deficiency/dysregulation, polymorphic lymphoproliferative disorders arising in immune deficiency/dysregulation, and lymphomas arising in immune deficiency/dysregulation. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Before Dr Leslie Sobin produced the first edition from 1967 to 1981, and the second over the course of 20 years, from 1982 to 2002. Leukemia [Internet]. Federal government websites often end in .gov or .mil. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. https://doi.org/10.1038/s41375-022-01625-x, DOI: https://doi.org/10.1038/s41375-022-01625-x. Show details Contents; Search term. Aetiology and recurrent genetic abnormalities in extranodal marginal zone lymphoma (EMZL) of various, Fig. Would you like email updates of new search results? Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract involving the stomach. Stroma-derived tumors of lymphoid tissue and tumor-like lesions have been included for the first time. We herein present an overview of the upcoming 5^th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. The last edition of the WHO classification of hematolymphoid tumors was the 4th edition released in 2008 and revised in 2017. The series is currently in its fifth edition, and each volume is prepared by a group of internationally recognized experts. Indolent NK-cell lymphoproliferative disorder of. Blood. Response to the Comments from the Groupe Francophone de Cytogntique Hmatologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors. The books in their entirety are subject to copyright by the publisher. 32, 39-41). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The CAC has been run by many of the same individuals with few changes for many years, and its selection process for new members is obscure. This family is organized into two separate entities: monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), with MBL having three distinct subtypes; low-count MBL or clonal B-cell expansion, CLL/SLL-type MBL, and non-CLL/SLL-type MBL. All resources are student and donor supported. 2022 Aug;43(Suppl 1):64-70. doi: 10.1007/s00292-022-01132-x. Consequently, adult-type entities that . Please contact us. B-ALL NOS, is to be reserved for cases that cannot be classi, even after comprehensive testing. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Revised 4th edition 5th edition Mutations of MAPK pathway ALK-positive histiocytosis Presence of ALK gene translocation (most commonly KIF5B::ALK) Response to ALK inhibitor therapy Multisystem systemic form occurs in infants- resolves slowly, spontaneously or with chemotherapy. Accessibility ISSN 0887-6924 (print), The WHO Classification of Haematolymphoid Tumours, https://doi.org/10.1038/s41375-022-01625-x, https://tumourclassification.iarc.who.int/welcome/, http://creativecommons.org/licenses/by/4.0/, Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2). doi: 10.1182/blood-2016-10-746933. ): World Health Organization classification of Tumours of Haematopoietic and Lymphoid Tissues. These subtypes are characterized by immune impairment with suboptimal response to vaccinations and increased risk of infection. As published , the first of these meetings set the draft classification (table of contents) to which authorship groups were assigned. ISSN 1476-5551 (online) We set about doing this, by converting the classification to a hierarchical taxonomy, entered into a database, and by paying careful attention to process management. eCollection 2023. PMC Physician and Resident Communities (MD / DO). The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Castleman disease is now subdivided into three separate disease classifications, which can be diagnosed using an integrated diagnostic algorithm. Lyon: IARC 2008. 2023 Jul 3;16(1):14. doi: 10.1186/s13039-023-00645-1. The International Consensus Classification (ICC) and World Health Organization (WHO) proposed significant changes to the diagnostic criteria of myelodysplastic syndromes (MDS) in 2022. DEEPA ANANTHA LAXMI N.V Follow. For further support with Google Translate, visit Google Translate Help. Summary of the relationship between, Fig. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Recently, the 5th edition of the WHO classification of hematolymphoid tumors was released, with the online version available since August 2022, and the print version expected to be out at the end of 2022. We read with great interest the recent publications on the Fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) [ 1, 2 ]. Jaffe ES, Harris N, Stein H, Vardiman JW (Eds. Nodal EBV-positive T- and NK-cell lymphoma. Cases classified in WHO-HAEM4R as CLL/SLL with15% of prolymphocytes are now classified as prolymphocytic progression of CLL, cases with <15% of prolymphocytes remain CLL/SLL in WHO-HAEM5. Neuro Oncol. This classification provided a novel framework for the recognition of individual disease entities based on a constellation of features, including morphology, immune . Epub 2022 Jun 22. Yassmine M.N. FOIA As in previous iterations, the tumors are stratified into benign and malignant varieties, with a separate section to address hematolymphoid neoplasms of the heart. Fig. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. Leukemia. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in This site needs JavaScript to work properly. Potka A, Przybyowicz-Chalecka A, Korolczuk M, Kandua Z, Ratajczak B, Kiernicka-Parulska J, Mierzwa A, Godziewska K, Jarmu-Szymczak M, Gil L, Lewandowski K. Mol Cytogenet. The resulting product is hoped to be a continuation and systematic evolution of the prior classifications, with the overarching goal of allowing for continuity in daily practice and ongoing clinical trials. The haematolymphoid tumours volume had the usual two editorial board meetings, the first in June 2021 and the second in November 2021. Gonzalez RS, Raza A, Propst R, Adeyi O, Bateman J, Sopha SC, Shaw J, Auerbach A. Arch Pathol Lab Med. The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors Weijie Li, MD, PHD Pages 1-21 PDF HTML XML Chapter 2 Infant Leukemia Overview of the hierarchical system of classification*, DLBCL-NOS, diffuse large B-cell lymphoma-not otherwise specified. ging the adoption of molecular testing where required, diagnostic criteria for each entity are de, nement of the diagnosis, and usually require the application, of advanced techniques. The https:// ensures that you are connecting to the The 5th edition includes, in addition to hematolymphoid neoplasms, reactive https://tumourclassification.iarc.who.int, https://doi.org/10.1038/s41375-022-01625-x, https://doi.org/10.1038/s41375-022-01620-2. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition - WHO - OMS - WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition (WHO classification of tumors series, 5th ed.). This has gained further importance as we continue to evolve the WHO Blue Books website (https://whobluebooks.iarc.fr), which permits even broader dissemination of the WHO classification and accessibility to it as a worldwide resource. Fig. 2022 Mar; 16(1):101-109. Monoclonal gammopathy of renal significance and cold agglutinin disease are two new entities that fall under the umbrella of plasma cell neoplasms/other diseases with paraproteins. 5. Epub 2022 Mar 21. [cited 2022 Aug 29]. Just got an email today that it will ship in September and is available to order at WHO. (in press). Outside the shared entities, unique proliferations are especially typical for various inborn errors of immunity (IEI). Overview of the 2022 WHO Classification of Thyroid Neoplasms. edition: B-cell lymphoid proliferations and lymphomas. Hematolymphoid tumors [Internet; beta version ahead of print (in progress)] Lyon (France): International Agency for Research on Cancer; 2022. The second editorial board considered the written evidence for each tumour type provided by the authorship groups. Hemolymphoreticular Neoplasias from the Ramazzini Institute Long-term Mice and Rat Studies on Aspartame. This information may be promotional in nature and is not associated with the, All content on this site is intended for healthcare professionals only. Epub 2022 Mar 14. The 3 Month (100 Day) MCAT Study Schedule Guide: 2022 Edition, http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition - WHO - OMS -, Stylus/World Health Organization - WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 8600 Rockville Pike Chapter 1. Alaggio R, Amador C, Anagnostopoulos, et al. 1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. Leukemia. This lymphoma shows a diffuse infiltrate of, MeSH Below, we provide part one of a summarized overview of the upcoming 5th edition, published on behalf of the WHO by Alaggio et al. The rare B-ALL with. official website and that any information you provide is encrypted I'm a first year with a strong interest in hemepath and am thinking of buying the 2008 4th edition, but should I wait for the 5th to come out? All content on this site is intended for healthcare professionals only. Parkash V, Aisagbonhi O, Riddle N, Siddon A, Panse G, Fadare O. Arch Pathol Lab Med. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms. The late Dr Paul Kleihues then joined him to produce the 3rd edition from 2000 to 2005, reducing the time taken to produce the series to just 5 years from the previous 20 years. Google Scholar. You must log in or register to reply here. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al., editors. Online ahead of print. Besides listing the entities of the classification, we highlight and explain changes from the revised 4 th edition. 10.36255/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors, REVISED LINEAGE-BASED CLASSIFICATION STRUCTURE AND REARRANGEMENT OF THE CONTENTS, NEWLY ADDED CATEGORIES, FAMILIES, ENTITIES, AND SUBTYPES, REVISED NOMENCLATURE AND TERMINOLOGY CHANGES, UPDATED CYTOGENETIC/MOLECULAR GENETIC INFORMATION. volume36,pages 17011702 (2022)Cite this article. Update from the 5th Edition of the World Health Organization Classification of Head and Neck . 3. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Final decisions were taken based on, taken in making changes to nomenclature. the entities are generally arranged in an order commencing with, rst time, in an effort to prevent the over-diagnosis of, lymphoma and to improve the recognition of clinicopathologically, distinct entities, non-neoplastic conditions mimicking lymphoma. Pathologie (Heidelb). The WHO classification of haematolymphoid tumours: response to Swerdlow et al. 2023 Jun 19;23(1):563. doi: 10.1186/s12885-023-10988-y. . Please enable it to take advantage of the complete set of features! 2023 Jun 2;13:1176698. doi: 10.3389/fonc.2023.1176698. It really is the basis of cancer science internationally. In addition, first, we sought public input on the initial outline (table of contents) of the classification by putting it out for public review and input on the WHO Blue Books website, with FAQs detailing the process followed. 0% found this document useful, Mark this document as useful, 0% found this document not useful, Mark this document as not useful, Save 5th Ed WHO 2022 Hematolymphoid For Later, , in close collaboration, further supported, by regular online meetings with the editorial team despite (and, possibly in part thanks to) the challenges encountered during the, COVID-19 pandemic. Clipboard, Search History, and several other advanced features are temporarily unavailable. This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register. With 420 experts involved in the volume as authors or editors, the range of expertise contributing to this volume is unprecedented. Quality-related issues identified to be addressed in the 5th edition related to the need to improve the quality of figures (an essential aspect, as we have switched to a two-column format with larger illustrations), the use of standardized international units [9, 10], HGNC/HGVS notation of genetics, avoidance of misleading terminology [11] and improved epidemiology. Online ahead of print. BMC Cancer. The WHO classification of tumors of various organ systems, also known as the WHO Blue Books, has provided a unified tumor classification system enabling people across the world to share their knowledge and research results. Gonzalez RS, Raza A, Propst R, Adeyi O, Bateman J, Sopha SC, Shaw J, Auerbach A. Arch Pathol Lab Med. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. 8. It may not display this or other websites correctly. Head Neck Pathol. 2022;36(7):17011702. Summary of the relationship between immunodeficiency-associated lymphoid proliferations and lymphomas as named and, Fig. ): World Health Organization classification of Tumours of Haematopoietic and Lymphoid Tissues. If you are a patient or carer, please visit the. The 2019 World Health Organization classification of tumours of the breast. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher. 4. For any comments or corrections, please email: WHO Blue Books Team, Clonal HaematopoiesisClonal haematopoiesisClonal cytopenias of undetermined significance, Myeloproliferative neoplasmsChronic myeloid leukaemiaChronic neutrophilic leukaemiaChronic eosinophilic leukaemia, not otherwise specifiedPolycythaemia veraEssential thrombocythaemiaPrimary myelofibrosisJuvenile myelomonocytic leukemiaMyeloproliferative neoplasm, not otherwise specifiedMastocytosisCutaneous mastocytosisSystemic mastocytosisMast cell sarcomaMyelodysplastic neoplasmsMyelodysplastic neoplasm with low blasts and isolated 5q deletionMyelodysplastic neoplasm with low blasts and SF3B1 mutationMyelodysplastic neoplasm with low blasts, not otherwise specifiedMyelodysplastic neoplasm with increased blastsMyelodysplastic neoplasm with fibrosisMyelodysplastic neoplasm, not otherwise specifiedMyelodysplastic neoplasm with biallelic TP53 alteration (provisional)Myelodysplastic neoplasm with other defined driver gene alterationsMyelodysplastic neoplasms / acute myeloid leukaemiaMyelodysplastic neoplasm / acute myeloid leukaemia with NPM1 mutationMyelodysplastic neoplasm / acute myeloid leukaemia with MECOM rearrangementMyelodysplastic neoplasm / acute myeloid leukaemia, NOSMyelodysplastic neoplasms of childhoodRefractory cytopenia of childhoodChildhood myelodysplastic syndromeMyelodysplastic neoplasms with proliferative evolutionChronic myelomonocytic leukaemiaMyelodysplastic neoplasm with proliferative evolution and neutrophiliaMyelodysplastic neoplasm with proliferative evolution, SF3B1 mutation and thrombocytosisMyelodysplastic neoplasm with proliferative evolution, not otherwise specified, Acute myeloid leukaemia with defining genetic abnormalitiesAcute promyelocytic leukaemiaAcute myeloid leukaemia with RUNX1-RUNX1T1 fusionAcute myeloid leukaemia with CBFB-MYH11 fusionAcute myeloid leukaemia with KMT2A rearrangementAcute myeloid leukaemia with DEK-NUP214 fusionAcute myeloid leukaemia RBM15-MKL1 fusionAcute myeloid leukaemia with BCR-ABL1 fusionAcute myeloid leukaemia with NUP98 rearrangementAcute myeloid leukaemia with other defined driver gene alterationsAcute myeloid leukemia with myelodysplasia-related cytogeneticsAcute myeloid leukaemia, defined by differentiationAcute myeloid leukaemia with minimal differentiationAcute myeloid leukaemia without maturationAcute myeloid leukaemia with maturationAcute basophilic leukaemiaAcute myeloid leukemia with myelomonocytic differentiationAcute myeloid leukemia with monocytic differentiationAcute myeloid leukemia with plasmacytoid dendritic cell differentiation (provisional)Pure erythroid leukaemiaAcute megakaryoblastic leukaemiaMyeloid sarcoma and othersMyeloid sarcoma, Myeloid neoplasms and proliferations associated with antecedent or predisposing conditionsMyeloid neoplasm post cytotoxic therapyMyelodysplastic neoplasm associated with germline predispositionAcute myeloid leukaemia following other haematolymphoid malignancyMyeloid proliferations associated with Down syndromeMyeloid neoplasm associated with malignant germ cell tumour, Myeloid/lymphoid neoplasm with PDGFRA rearrangementMyeloid/lymphoid neoplasm with PDGFRB rearrangementMyeloid/lymphoid neoplasm with FGFR1 rearrangementMyeloid/lymphoid neoplasm with PCM1-JAK2 fusion, Mixed-phenotype acute leukaemia with BCR-ABL1 fusionMixed-phenotype acute leukaemia with KMT2A rearrangementMixed-phenotype acute leukaemia, B/myeloidMixed-phenotype acute leukaemia, T/myeloidAcute leukaemia of ambiguous lineage, not otherwise specified, Plasmacytoid dendritic cell neoplasmsMature plasmacytoid dendritic cell proliferationBlastic plasmacytoid dendritic cell neoplasm, Langerhans cells neoplasmsLangerhans cell histiocytosisLangerhans cell sarcoma, Histiocytic neoplasmsJuvenile xanthogranulomaErdheim-Chester diseaseRosai-Dorfman DiseaseALK related histiocytosisHistiocytic sarcoma, Interdigitating dendritic cell neoplasmsIndeterminate dendritic cell tumourInterdigitating dendritic cell sarcoma, Introduction to B-cell lymphoproliferative disorders and neoplasms, Castleman diseaseIgG4 related diseaseReactive B-cell rich lymphoid proliferations that can mimic lymphoma, B acute lymphoblastic leukaemiaB acute lymphoblastic leukemia with BCR-ABL1 fusionB acute lymphoblastic leukemia with KMT2A rearrangementB acute lymphoblastic leukemia with ETV6-RUNX1 fusionB acute lymphoblastic leukemia/lymphoma, BCR-ABL1-like featuresB acute lymphoblastic leukemia/lymphoma with other defined driver gene alterationsB-lymphoblastic leukaemia/lymphoma with hyperdiploidyB-lymphoblastic leukaemia/lymphoma with hypodiploidyB acute lymphoblastic leukemia with germline predispositionB acute lymphoblastic leukemia with DUX4 rearrangement (provisional)B acute lymphoblastic leukemia with MEF2D rearrangement (provisional)B acute lymphoblastic leukemia with ZNF384 rearrangement (provisional)B acute lymphoblastic leukemia/lymphoma, not otherwise specified, Chronic lymphocytic leukaemia/small lymphocytic lymphomaMonoclonal B-cell lymphocytosisChronic lymphocytic leukaemia/small lymphocytic lymphomaSplenic B-cell neoplasmsHairy cell leukaemiaSplenic B-cell neoplasm with hairy cell features (formerly HCLv)Splenic diffuse red pulp small B-cell lymphomaSplenic marginal zone lymphomaLymphoplasmacytic lymphomaLymphoplasmacytic lymphomaMarginal zone lymphomaIndolent clonal marginal zone B-cell expansionsExtranodal marginal zone lymphomaNodal marginal zone lymphomaFollicular lymphomaIn situ follicular B cell neoplasmFollicular lymphomaPaediatric-type follicular lymphomaDuodenal-type follicular lymphomaGonadal follicular lymphomaCutaneous follicle centre neoplasmsPrimary cutaneous follicle centre lymphomaMantle cell lymphomaIn situ mantle cell neoplasmMantle cell lymphomaLeukaemic non-nodal mantle cell lymphomaTransformations from indolent B cell lymphomasTransformations from indolent B cell lymphomasLarge B-cell lymphomaDiffuse large B-cell lymphoma, not otherwise specifiedT-cell/histiocyte-rich large B-cell lymphomaHigh-grade B-cell lymphoma with MYC and BCL2 rearrangementsALK-positive large B-cell lymphomaLarge B-cell lymphoma with IRF4 rearrangementHigh grade B-cell lymphoma with 11q aberrationLymphomatoid granulomatosisEBV-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphoma associated with chronic inflammationFibrin-associated diffuse large B-cell lymphomaHHV8-unrelated effusion large B-cell lymphomaPlasmablastic lymphomaPrimary diffuse large B-cell lymphoma of immune-privileged sitesPrimary cutaneous diffuse large B-cell lymphoma (formerly leg type)Intravascular large B-cell lymphomaPrimary mediastinal large B-cell lymphomaMediastinal grey zone lymphoma Burkitt lymphomaBurkitt lymphomaHigh-grade B-cell lymphoma not otherwise specifiedHigh-grade B-cell lymphoma, not otherwise specified HHV8-associated B-cell neoplasms and lymphoproliferative disordersPrimary effusion lymphomaHHV8-positive diffuse large B-cell lymphoma, not otherwise specifiedHHV8-positive germinotropic lymphoproliferative disorderImmunodeficiency-associated lymphoproliferative disordersPrimary immunodeficiency associated lymphoproliferative disordersSecondary immunodeficiency associated lymphoproliferative disorders, Classic Hodgkin lymphomaNodular lymphocyte predominant Hodgkin lymphoma, Monoclonal gammopathiesIgM Monoclonal gammopathy of undetermined significanceNon-IgM monoclonal gammopathy of undetermined significanceMonoclonal gammopathy of renal significanceMonoclonal immunoglobulin deposition diseasesImmunoglobulin-related (AL) amyloidosisMonoclonal immunoglobulin deposition diseasesHeavy chain diseasesMu heavy chain diseaseGamma heavy chain diseaseAlpha heavy chain diseasePlasma cell neoplasmsPlasmacytomaPlasma cell myelomaPlasma cell neoplasms with associated paraneoplastic syndrome, Kikuchi diseaseIndolent T-lymphoblastic proliferationAutoimmune lymphoproliferative syndrome, T acute lymphoblastic leukaemia / lymphomaT acute lymphoblastic leukemia / lymphoma, not otherwise specifiedEarly T precursor acute lymphoblastic leukaemia / lymphoma, Mature T-cell leukemiasT-cell prolymphocytic leukaemiaT-cell large granular lymphocytic leukaemiaAdult T-cell leukaemia/lymphomaSezary syndromePrimary cutaneous T-cell neoplasmPrimary cutaneous CD4+ small or medium T-cell lymphoproliferative disorderMycosis fungoidesLymphomatoid papulosisPrimary cutaneous anaplastic large cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaPrimary cutaneous gamma/delta T-cell lymphomaPrimary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (provisional)Primary cutaneous acral CD8-positive T-cell lymphomaPrimary cutaneous T-cell lymphoma, NOSIntestinal T-cell neoplasms and lymphoproliferative disordersIndolent T-cell lymphoproliferative disorder of the gastrointestinal tractEnteropathy-associated T-cell lymphomaMonomorphic epitheliotropic intestinal T-cell lymphomaIntestinal T-cell lymphoma, NOSHepatosplenic T-cell lymphomaHepatosplenic T-cell lymphomaAnaplastic large cell lymphomaAnaplastic large cell lymphoma, ALK positiveAnaplastic large cell lymphoma ALK negative (DUSP22/TP63/NOS)Anaplastic large cell lymphoma, breast implant-associatedPeripheral T-cell lymphoma with TFH phenotypeFollicular T-cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphoma with TFH phenotypePeripheral T-cell lymphomaPeripheral T-cell lymphoma, NOSEBV-positive nodal T-cell lymphomaEBV-positive lymphoproliferative diseases of childhoodSevere mosquito bite allergyHydroa vacciniforme-like lymphoproliferative disorderChronic active EBV infection of T- and NK-cell type, systemic formSystemic EBV+ T-cell lymphoma of childhood, Chronic lymphoproliferative disorder of NK cellsIndolent NK-cell lymphoproliferative disorder of the gastrointestinal tract (provisional)Aggressive NK-cell leukaemiaExtranodal NK/T-cell lymphoma, nasal typeEBV-positive nodal NK-cell lymphomaNK acute lymphoblastic leukemia (provisional), Follicular dendritic cell neoplasmsFollicular dendritic cell sarcomaInflammatory EBV+ follicular dendritic cell sarcomaFibroblastic reticular cell tumour, Littoral cell angiomaLittoral cell angioma, Fanconi anaemiaBloom syndromeAtaxia-telangiectasia syndromeRASopathiesFor any comments or corrections, please email: WHO Blue Books Team This document should not be reproduced without direct permission from IARC.
Gynecologist Bay Ridge, Articles W